Litigation summary

As of my analysis date of May 13, 2026, U.S. Patent No. 12,174,106 is involved in at least one known litigation proceeding.

Based on publicly available records, including U.S. Securities and Exchange Commission (SEC) filings and documents from the U.S. Patent and Trademark Office's Patent Trial and Appeal Board (PTAB), the following litigation has been identified:

---

United States District Court for the District of Delaware

• Case Number: 1:24-cv-00945
• Plaintiff(s): Beckman Coulter, Inc.
• Defendant(s): Cytek Biosciences, Inc.
• Jurisdiction: U.S. District Court for the District of Delaware
• Filing Date: The initial complaint was filed in August 2024. An amended complaint adding the '106 patent was filed in late 2024 or early 2025.
• Outcome or Current Status:
  • This is an active patent infringement case. Beckman Coulter, Inc. originally sued Cytek Biosciences, Inc. in August 2024, asserting related patents.
  • Beckman Coulter later filed an amended complaint to include allegations of infringement of U.S. Patent No. 12,174,106, which was issued on December 24, 2024.
  • In response, Cytek Biosciences, Inc. filed an answer denying liability and filed a counterclaim for false patent marking.
  • According to court documents, a jury trial is scheduled for August 17, 2026.
  • Recent filings indicate that as of May 2026, the '106 patent is no longer being asserted in this district court case. This change in litigation strategy may affect the ongoing proceedings.

---

U.S. Patent Trial and Appeal Board (PTAB)

• Case Number: PGR2025-00084
• Petitioner: Cytek Biosciences, Inc.
• Patent Owner: Beckman Coulter, Inc.
• Jurisdiction: U.S. Patent and Trademark Office, Patent Trial and Appeal Board
• Filing Date: Approximately late 2024 or early 2025.
• Outcome or Current Status:
  • This was a Post-Grant Review (PGR) proceeding initiated by Cytek Biosciences, Inc. to challenge the validity of the '106 patent.
  • The PTAB denied the institution of the PGR. This means the board found that the petitioner did not establish that it was more likely than not that at least one of the challenged claims was unpatentable.
  • The proceeding was terminated, and the patent claims remain valid and unaltered by this challenge. The patent owner, Beckman Coulter, Inc., has argued that Cytek has taken inconsistent claim construction positions between the district court litigation and the PTAB proceeding.